Company Overview and News
Gascoyne Resources Ltd (ASX:GCY) surged 31% after receiving bonanza-grade results of up to 987 g/t gold in the first reverse circulation (RC) drilling at Tanqueray prospect of the Dalgaranga Gold Project in WA.
Gascoyne Resources has returned gold results of up to 1450g/t within an 8 metre wide zone from drilling at the Dalgaranga gold project in the Murchison region of Western Australia.
Zenith Energy Ltd (ASX:ZEN) (LON:ZEN), an independent power producer that listed in May 2017, has reported a net profit after tax of $8.47 million for the 2018 financial year, an increase of 171% on last year.
GCY NEM ZEE DCN LNSTY CANIF
Diggers and Dealers Mining Forum 2018 will welcome a pack of gold plays to the stage this week to speak about their companies and the precious metal. Here’s who’s going.
ELKMF OCANF PILBF RMS EVN GCY SCEXF SNDFY WAF NST DCN AU IGO AULGF RSG OGC GOR LONCF MSR RMGGF SFR SBM AGG CAHPF PLS WFRSF IIDDY RGRNF ORG PNR LN NESRF SFRRF RMGGY RRL OGDCF NHRNY CANWF RMLRF SAR
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
ELKMF NCMGF NCM BLT EVN GCY SCEXF WAF NST DCN FTMNF CDNL LUG GOR CAHPF FMG WFRSF BHPBF CDV FSUGY NESRF NCMGY FSUMF BHP BBL BHP NHRNY BHPLF SAR
Gascoyne Resources Ltd (ASX:GCY) has received high-grade results which have potential to add to the 1 million ounce gold resource at the Glenburgh project.
Diggers and Dealers Mining Forum will attract some higher profile Australian mining companies to Kalgoorlie-Boulder next week, with the forum’s chairman tipping a ‘buoyant’ Diggers with great presentations.
NCMGF PILBF NCM RMS GCY EVN SCEXF SNDFY NST DCN IGO AGY ARYMF RSG MMI RMGGF SFR SBM CAHPF FMG WNARF WSA PLS IIDDY FSUGY NESRF NCMGY FSUMF SFRRF RMGGY NHRNY PEX RMLRF SAR
Gascoyne Resources Ltd (ASX:GCY) has fully commissioned the 2.5 million tonnes per annum (mtpa) processing plant and completed a performance test at its Dalgaranga Gold Project in Western Australia.
Gascoyne Resources is only 10 days from first gold production at the Dalgaranga project in Western Australia, under budget and six weeks ahead of schedule.
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to ASX:GCY / GASCOYNE RESOURCES LIMITED on message board site Silicon Investor.
|SPIDER u0026 RICOu0027S u0027NO-BASHu0027 THREAD FOR LGCY !!!||SPIDER u0026 RICOu0027S u0027NO-BASHu0027 THREAD FOR LGCY !!!||SPIDER u0026 RICOu0027S u0027NO-BASHu0027 THREAD FOR LGCY !!!|